Pharma giant Gilead Sciences agreed to pay hundreds of millions of dollars to state health insurance programs after admitting ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the company announced it ...

Gilead Sciences (NASDAQ:GILD) has reached a $202M deal with a group of attorneys general in the U.S. to settle allegations ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

The World Health Organization (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...

Gilead Sciences will pay more than $200 million after admitting to a multi-year illegal kickback scheme that pushed its HIV drugs through lavish perks for prescribers. New York Attorney General ...

The scheme involved incentives to healthcare providers, leading to false claims to government programs like Medicaid.

CHICAGO Attorney General Kwame Raoul, as part of a bipartisan coalition of 49 attorneys general, announced a $202 million multistate settlement agreement ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...